This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Purtilo DT, Cassel CK, Yang JP, Harper R . X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975; 1: 935–940.
Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998; 20: 129–135.
Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995; 38: 471–478.
Bond J, Shahdapuri R, McMahon C, O'Marcaigh A, Cotter M, Smith O . Successful treatment of acute Epstein-Barr virus infection associated with X-linked lymphoproliferative disorder with rituximab. Paediatr Blood Cancer 2007; 49: 761–762.
Lee TL, Law HKW, Chan GCF, Ha SY, Ho MHK, Chan KW et al. Successful treatment of X-linked lymphoproliferative disease (XLP) with anti-CD20 monoclonal antibody (rituximab) followed by mismatched unrelated cord blood transplantation. HK J Paediatr 2006; 11: 210–214.
Hoffman T, Heilman C, Madsen HO, Vindelov L, Schmeigelow K . Matched unrelated allogeneic bone marrow transplantation for recurrent malignant lymphoma in a patient with X-linked lymphoproliferative disease (XLP). Bone Marrow Transplant 1998; 22: 603–604.
Lankester AC, Visser LF, Hartwig NG, Bredius RGM, Gaspar HB, van der Burg M et al. Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant 2005; 36: 99–105.
Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe LA, Dvorak CC, Horn BN . Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 2008; 42: 83–91.
Cohen JM, Sebire NJ, Harvey J, Gapsar HB, Cathy C, Jones A et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007; 110: 2209–2214.
Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006; 107: 1233–1236.
Slatter MA, Bhattacharya A, Abinun M, Flood TJ, Cant AJ, Gennery AR . Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant 2005; 35: 683–689.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Haslam, K., Molloy, K., Langabeer, S. et al. Stable low-level donor-cell engraftment in a patient with X-linked lymphoproliferative disease following matched unrelated allo-SCT. Bone Marrow Transplant 46, 1263–1264 (2011). https://doi.org/10.1038/bmt.2010.266
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.266